INVO Bioscience Files 8-K: Material Agreement & Equity Sales
Ticker: IVF · Form: 8-K · Filed: May 6, 2024 · CIK: 1417926
| Field | Detail |
|---|---|
| Company | Invo Bioscience, INC. (IVF) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
INVO Bioscience signed a big deal and sold some stock. Details to follow.
AI Summary
INVO Bioscience, Inc. announced on May 1, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this summary.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity securities, which can introduce financial and operational risks if not managed properly.
Key Players & Entities
- INVO Bioscience, Inc. (company) — Registrant
- May 1, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 5582 Broadcast Court Sarasota, Florida 34240 (address) — Principal executive offices
- (978) 878-9505 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by INVO Bioscience, Inc. on May 1, 2024?
The filing states that INVO Bioscience, Inc. entered into a material definitive agreement on May 1, 2024, but the specific details of this agreement are not disclosed in the provided text.
What type of equity securities were sold by INVO Bioscience, Inc.?
The filing mentions 'Unregistered Sales of Equity Securities' as an item reported, but does not specify the type or amount of securities sold.
When was INVO Bioscience, Inc. incorporated?
INVO Bioscience, Inc. was incorporated in Nevada, as indicated by the filing.
What is the principal executive office address for INVO Bioscience, Inc.?
The principal executive offices of INVO Bioscience, Inc. are located at 5582 Broadcast Court, Sarasota, Florida 34240.
What is the filing date for this 8-K report?
This 8-K report was filed on May 6, 2024.
Filing Stats: 1,065 words · 4 min read · ~4 pages · Grade level 11.9 · Accepted 2024-05-06 17:30:18
Key Financial Figures
- $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
- $5.00 — preferred stock at a price per share of $5.00 per share in a private offering, to be
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex2-1.htm (EX-2.1) — 23KB
- ex10-1.htm (EX-10.1) — 29KB
- 0001493152-24-017951.txt ( ) — 281KB
- invo-20240501.xsd (EX-101.SCH) — 3KB
- invo-20240501_lab.xml (EX-101.LAB) — 33KB
- invo-20240501_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 2.1 Third Amendment to Agreement and Plan of Merger by and among INVO Bioscience, Inc., INVO Merger Sub, Inc., and NAYA Biosciences, Inc. dated as of May 1, 2024. 10.1 Amendment to Securities Purchase Agreement by and between INVO Bioscience, Inc. and NAYA Biosciences, Inc. dated as of May 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 6, 2024 INVO BIOSCIENCE, INC. By: /s/ Steven Shum Steven Shum Chief Executive Officer